Spots Global Cancer Trial Database for cyclophosphamide (cytoxan)
Every month we try and update this database with for cyclophosphamide (cytoxan) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L | NCT00807599 | Multiple Myelom... | Stem cell trans... lenalidomide an... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis | NCT01383759 | Light Chain Dep... Light Chain and... Monoclonal Immu... Amyloidosis | Bortezomib/Dexa... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis | NCT01383759 | Light Chain Dep... Light Chain and... Monoclonal Immu... Amyloidosis | Bortezomib/Dexa... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility | NCT00617370 | Breast Cancer Adenocarcinoma ... | epirubicin, cyc... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L | NCT00807599 | Multiple Myelom... | Stem cell trans... lenalidomide an... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | NCT00877110 | Neuroblastoma Bone Marrow, Sy... | cyclophosphamid... | - | Memorial Sloan Kettering Cancer Center | |
| Cord Blood Transplant in Adults With Blood Cancers | NCT05884333 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Myeloproliferat... Non-Hodgkin's L... | Conditioning Ch... Cord blood graf... | 21 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab | NCT01416974 | Leukemia | cyclophosphamid... modified T cell... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility | NCT00617370 | Breast Cancer Adenocarcinoma ... | epirubicin, cyc... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab | NCT01416974 | Leukemia | cyclophosphamid... modified T cell... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Cord Blood Transplant in Adults With Blood Cancers | NCT05884333 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Myeloproliferat... Non-Hodgkin's L... | Conditioning Ch... Cord blood graf... | 21 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. | NCT00739141 | Leukemia Myelodysplastic... Non-Hodgkins Ly... Chronic Myeloge... Hodgkins Lympho... | fludarabine, cy... | 18 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies | NCT01682226 | Leukemia Myelodysplastic... Lymphoma | CliniMACS Fract... CliniMACS Fract... Haploidentical ... | 2 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma | NCT01492673 | Neuroblastoma Sarcoma | Cyclophosphamid... | - 21 Years | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
